School of Medicine


Showing 21-30 of 52 Results

  • Cornelia L. Dekker, M.D.

    Cornelia L. Dekker, M.D.

    Professor (Research) of Pediatrics (Infectious Diseases), Emerita

    Current Research and Scholarly Interests The Stanford-LPCH Vaccine Program provides an infrastructure for conducting clinical studies of vaccines in children and adults. We conduct immunology studies of seasonal influenza vaccines in twins, in a longitudinal cohort of young and elderly adults and studies of various vaccine candidates for NIH and industry. Additionally, we were a CDC Clinical Immunization Safety Assessment site for 10 years working on safety issues concerning licensed vaccines.

  • Lauren Destino

    Lauren Destino

    Clinical Associate Professor, Pediatrics

    Bio Lauren Destino, MD, is the Associate Medical Director of the Pediatric Hospital Medicine Division and Associate Medical Director of the acute care floor at Lucile Packard Children’s Hospital (LPCH) Stanford and a clinical assistant professor at Stanford Univeristy. She was a site co-Investigator for the I-PASS study at Stanford and is the site Principal Investigator for the PCORI grant, Bringing I-PASS to the Bedside: A Communication Bundle to Improve Patient Safety and Experience. She is involved in a number of quality and process improvement related activities at LPCH. She is the director for a required quality improvement rotation for residents and co-directs the scholarly concentration for quality and process improvement. She is also the MOC portfolio manager for LPCH Stanford’s MOC part IV portfolio. Her research interests include communication among the care team (inclusive of patients and families) as well as quality and quantity of time trainees spend in patient/family communication.

  • Daniel Dever

    Daniel Dever

    Instructor, Pediatrics - Stem Cell Transplantation

    Bio Dr. Daniel Dever is a Research Instructor in the laboratory of Dr. Matthew Porteus at Stanford University, in the Department of Pediatrics, Division of Stem Cell Transplantation and Regenerative Medicine. He completed his PhD in molecular toxicology at the University of Rochester where he studied the mechanisms of the aryl hydrocarbon receptor in mediating cerebellar transcriptional programs. During his postdoctoral work in the Porteus group, he (with others) developed a CRISPR/Cas9-based beta-globin (HBB) gene editing by homologous recombination methodology (gene targeting) in CD34+ hematopoietic stem cells as a potential therapeutic strategy to treat severe sickle cell disease. Dr. Dever (along with collaborators) has now successfully used this methodology to efficiently target >15 genes in primary blood cells that are associated with hematopoiesis, hematopoietic genetic diseases, hematopoietic malignancies, or safe harbor sites. Dr. Dever's primary research interests are to continue to leverage CRISPR/Cas9-based genome editing technologies to study the molecular mechanisms of gene targeting in human hematopoietic stem cells with the ultimate goal of optimizing and further developing novel cell and gene therapies for disease of the blood and the immune system. Currently, he is leading IND-enabling preclinical efficacy, feasibility, safety and tumorigenicity studies for FDA approval of a first-in-human clinical trial at Stanford in 2018 for the treatment of severe sickle cell disease using CRISPR/Cas9-based HBB gene targeting in autologous hematopoietic stem cells.